CagriSema side effects often include nausea, vomiting, and constipation. Learn common, serious, and long-term risks of this investigational weight-loss drug.
CagriSema side effects are mainly gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain are the reactions reported most often in clinical trials. The drug is an investigational combination of cagrilintide and semaglutide, so its side effect profile overlaps heavily with GLP-1 medications already on the market. Serious but uncommon risks include gallbladder disease, pancreatitis, and low blood sugar when it is combined with insulin or sulfonylureas.
What Is CagriSema?
CagriSema is a once-weekly injectable that pairs cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 receptor agonist. Novo Nordisk developed it for chronic weight management and type 2 diabetes. Both components slow stomach emptying and reduce appetite signals in the brain, which is why the side effects tend to cluster in the digestive tract.
The combination is still experimental. CagriSema is not FDA-approved for human use in the United States, and outside of a clinical trial it is not legally available by prescription.
Most Common CagriSema Side Effects
In the REDEFINE phase 3 program, gastrointestinal events were by far the most frequently reported side effects, and most were mild to moderate. Symptoms often appear within the first few days after an injection and again after each dose increase.
| Side effect | How often it is reported | What it usually feels like |
|---|---|---|
| Nausea | Most common overall | Queasiness, especially after fatty or large meals |
| Vomiting | Common | Usually linked to nausea; can lead to dehydration |
| Diarrhea | Common | Loose stools, urgency, cramping |
| Constipation | Common | Infrequent or difficult bowel movements |
| Abdominal pain | Common | Bloating, pressure, or cramping |
| Headache | Less common | Dull ache, often in the first days after dosing |
| Fatigue | Less common | Low energy, partly from reduced food intake |
| Injection-site reactions | Less common | Redness, itching, or a small bruise |
Gastrointestinal Effects
Nausea is the single most reported complaint, and it is usually worst during the first weeks of treatment and during dose escalation. Eating smaller, lower-fat meals and stopping when full can reduce the intensity.
Because cagrilintide side effects and semaglutide side effects overlap so closely, researchers often cannot tell which component is responsible for a specific reaction.
Other Common Complaints
- Hair thinning or shedding, often tied to rapid weight loss
- Changes in taste
- Reflux or indigestion
- Loss of lean muscle mass when protein intake and resistance training are inadequate
Serious Side Effects and Warnings
Serious reactions are uncommon, but they are the reason CagriSema requires medical supervision.
- Gallbladder disease. Rapid weight loss raises the risk of gallstones and gallbladder inflammation. Pain in the upper right abdomen that radiates to the back or shoulder needs prompt evaluation.
- Pancreatitis. Severe, persistent abdominal pain that may radiate to the back can signal pancreatitis, a rare but serious complication of GLP-1 and amylin-based drugs.
- Hypoglycemia. Low blood sugar is mainly a concern when CagriSema is used together with insulin or sulfonylureas.
- Kidney injury. Persistent vomiting or diarrhea can cause dehydration that stresses the kidneys.
- Thyroid C-cell tumors. Semaglutide carries a boxed warning based on rodent studies. CagriSema is not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2.
- Delayed stomach emptying. Gastroparesis can worsen with treatment and may raise the risk of aspiration during anesthesia.
Anyone who develops severe abdominal pain, persistent vomiting, signs of dehydration, or vision changes should seek medical care rather than waiting for the next scheduled dose.
How CagriSema Compares With Other Weight-Loss Drugs
| Treatment | Common side effects | Notable serious risks | FDA status |
|---|---|---|---|
| CagriSema (cagrilintide + semaglutide) | Nausea, vomiting, diarrhea, constipation | Gallstones, pancreatitis, hypoglycemia | Investigational |
| Semaglutide (Wegovy, Ozempic) | Nausea, vomiting, diarrhea, constipation | Gallstones, pancreatitis, thyroid C-cell warning | Approved for weight loss and diabetes |
| Tirzepatide (Zepbound, Mounjaro) | Nausea, diarrhea, vomiting, constipation | Gallstones, pancreatitis, hypoglycemia | Approved for weight loss and diabetes |
| Cagrilintide alone | Nausea, diarrhea, constipation | Similar digestive and gallbladder concerns | Investigational |
The overall pattern is familiar: every incretin-based weight-loss drug causes gastrointestinal symptoms in a meaningful share of users. CagriSema does not appear to introduce a brand-new category of side effect, but it combines two active drugs, so the total burden can feel heavier for some people.
People shopping outside regulated trials frequently search for reta cagri blend side effects, yet no controlled human trial has tested that combination and its risk profile is genuinely unknown. The same caution applies to aod 9604 and tirzepatide together side effects, a pairing that has never been studied in a proper clinical study.
Other injectable therapies have their own profiles. Vyleesi is an unrelated treatment for low sexual desire, and vyleesi side effects such as nausea, flushing, and headache do not overlap meaningfully with CagriSema's digestive profile.
Who Should Avoid CagriSema?
CagriSema is not appropriate for everyone, and screening before treatment matters.
- People with a personal or family history of medullary thyroid carcinoma or MEN2
- Anyone who is pregnant, planning pregnancy, or breastfeeding
- Patients with a history of pancreatitis
- People with severe gastroparesis or a prior bowel obstruction
- Anyone with active gallbladder disease
Alcohol use, certain diabetes medications, and oral contraceptives can interact with the drug's effects, so a full medication review with a clinician is essential.
How to Manage Side Effects
- Start low and go slow. Slower dose escalation gives the gut time to adapt.
- Eat smaller, lower-fat meals and stop eating at the first sign of fullness.
- Stay hydrated with water, broth, or electrolyte drinks, especially during vomiting or diarrhea.
- Prioritize protein and resistance training to protect lean muscle.
- Track symptoms and report anything severe to your care team promptly.
Most people find that side effects ease after the first few weeks at a stable dose. Anyone whose symptoms interfere with daily life should talk to a healthcare professional about adjusting the dose or switching treatments.
Is CagriSema FDA-Approved?
CagriSema is not FDA-approved for human use in the United States, and it cannot be prescribed outside of a clinical trial. Any product advertised online as CagriSema is unregulated, unverified, and potentially unsafe. People considering prescription weight-loss medication should consult a licensed clinician about approved options instead.
Frequently Asked Questions
What are the most common CagriSema side effects?
Nausea, vomiting, diarrhea, constipation, and abdominal pain are the most frequently reported side effects of CagriSema. They usually appear shortly after an injection and are worst during the first weeks of treatment or after a dose increase. Most cases are mild to moderate and ease as the body adjusts.
Is CagriSema FDA-approved?
No. CagriSema is an investigational drug and has not been approved by the FDA for weight loss, diabetes, or any other use in the United States. It is only available through clinical trials, so any CagriSema sold online should be treated as unregulated and unsafe.
How long do CagriSema side effects last?
Gastrointestinal side effects typically peak in the first one to two weeks after starting treatment or increasing the dose, then fade within days to a few weeks. Some people have lingering nausea or constipation for months, especially at higher doses. Persistent or severe symptoms should be reported to a healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.